In patients scheduled for major elective orthopaedic surgery, with a baseline haemoglobin of 10 to 13 g/ dl, the incidence of thrombotic/ vascular events (most of which were DVTs), in the overall patient population of the clinical trials, appeared to be similar across the different epoetin alfa dosing groups and placebo group, although the clinical experience is limited.
Plaanilises korras olulist ortopeedilist operatsiooni ootavatel patsientidel, kelle hemoglobiinisisaldus oli ravieelselt 10- 13 g/ dl, oli trombootiliste/ vaskulaarsete tüsistuste (enamik neist DVT) esinemissagedus kõikide kliiniliste uuringute lõikes alfaepoetiin- ravigruppides ja platseebogrupis sarnane; kliiniline kogemus on siiski piiratud.